DataMeds Acquires Helomics for $1.5M in Stock and Convertible Note with Full-Ratchet Anti-Dilution
MEDS has more than doubled off its 52-week low of $0.823 on elevated volume (44× avg).
Summary
DataMeds AI acquired Helomics from Axe Compute for 636,328 shares (19.99% of outstanding) plus a $1.36M convertible note at $1.00/share with full-ratchet anti-dilution. The deal brings a CLIA/CAP-certified oncology lab and $1.5M cash, but the note's reset provisions could amplify future dilution.
Key Events · M&A and Partnerships · MEDS
-
Helomics Acquisition Completed
DataMeds acquired 100% of Helomics Corporation from Axe Compute on September 11, 2026, gaining a CLIA/CAP-certified AI cancer diagnostics lab and precision oncology CRO business.
-
Consideration: 19.99% Dilution Plus Note
Purchase price was 636,328 shares (19.99% of pre-deal outstanding) plus a $1,363,672 convertible note at $1.00/share — total stated value $1.5M. Helomics came with $1.5M cash and no third-party debt.
-
Full-Ratchet Anti-Dilution on Note
The convertible note carries full-ratchet protection: any future equity issuance below $1.00 automatically resets the conversion price lower, potentially increasing dilution for existing shareholders.
-
Stockholder Vote Required Within 75 Days
DataMeds must hold a stockholder meeting within 75 days to approve note conversion under Nasdaq Rule 5635(d); the note auto-converts upon approval.
Analysis · MEDS · Trade & Services
DataMeds AI completed its acquisition of Helomics, an AI cancer diagnostics lab and precision oncology CRO, from Axe Compute. The consideration includes 636,328 shares — equal to 19.99% of the company's pre-deal outstanding shares — plus a $1,363,672 convertible note at a $1.00 conversion price. The note carries a full-ratchet anti-dilution provision, meaning any future equity issuance below $1.00 automatically lowers the conversion price, which could significantly increase dilution for existing holders. Stockholder approval is required within 75 days under Nasdaq Rule 5635(d). Against the backdrop of DataMeds' going-concern warning and Nasdaq delisting risk disclosed in its August 10-Q, this acquisition adds an oncology diagnostics business with $1.5M in cash and no third-party debt, but the 19.99% share issuance and convertible note terms create meaningful overhang.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $6.12 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.82 to $75.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.